Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

Abroad (travel likely)Active Not RecruitingPHASE2

Conditions

Postural Orthostatic Tachycardia Syndrome (POTS)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mercy Gilbert Medical Center, Gilbert, Arizona, United States
North County Neurology Associates, Carlsbad, California, United States
Stanford University, Palo Alto, California, United States
Southern California Heart Specialists, Pasadena, California, United States
Yale University, New Haven, Connecticut, United States
Innovative Research of West Florida, Inc., Clearwater, Florida, United States
Indiana University Health Neuroscience Center, Indianapolis, Indiana, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
Saint Luke's MidAmerica Heart Institute, Kansas City, Missouri, United States
New York University Langone, New York, New York, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
University of Texas Southwestern, Dallas, Texas, United States
University of Utah, Salt Lake City, Utah, United States
University of Calgary, Calgary, Alberta, Canada

Study leads

Clinical Trial Management
Study Director
Regeneron Pharmaceuticals

View source on ClinicalTrials.gov